Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma 58Advanced Solid Tumors 53Mesothelioma, Malignant 51Solid Tumors 43Solid Tumor 35Advanced Solid Tumor 23Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 12Ovarian Neoplasms 10Melanoma 10Esophageal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Retinoblastoma 9Carcinoma, Renal Cell 9Unspecified Adult Solid Tumor, Protocol Specific 8Solitary Fibrous Tumor, Pleural 8Sarcoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 7Uterine Cervical Neoplasms 6Malignant Solid Tumor 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Solid Tumor, Adult 5Osteosarcoma 5Metastatic Solid Tumors 5Liver Neoplasms 5Colorectal Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Select Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT03515551 2022-03-11

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Immunocore Ltd

Phase 1/2 Terminated
29 enrolled 25 charts
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡